Abstract
Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. A decrease of dose to 30 mg is recommended for those with moderate renal insufficiency, weight ≤ 60 kg or simultaneous administration of strong P-glycoprotein inhibitors. At this time, it is not recommended for use in persons with either end stage renal disease or with GFR exceeding 95 mL/min. Shorter half-life averaging 8-10 hours may translate into a safer profile. With a fast onset of action of ~1.5 hours and relatively high bioavailability, edoxaban is an alternative for patients who may not be good candidates for warfarin therapy due to multiple limitations that vitamin K anticoagulation entails. No clear benefits of edoxaban have been reported to date compared to the other available factor Xa inhibitors.
Keywords: Edoxaban, oral anticoagulation, pharmacodynamics, pharmacokinetics.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy
Volume: 13 Issue: 2
Author(s): Maryna Popp Switzer, Priyanka Wani, Sucheta Gosavi and Debabrata Mukherjee
Affiliation:
Keywords: Edoxaban, oral anticoagulation, pharmacodynamics, pharmacokinetics.
Abstract: Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. A decrease of dose to 30 mg is recommended for those with moderate renal insufficiency, weight ≤ 60 kg or simultaneous administration of strong P-glycoprotein inhibitors. At this time, it is not recommended for use in persons with either end stage renal disease or with GFR exceeding 95 mL/min. Shorter half-life averaging 8-10 hours may translate into a safer profile. With a fast onset of action of ~1.5 hours and relatively high bioavailability, edoxaban is an alternative for patients who may not be good candidates for warfarin therapy due to multiple limitations that vitamin K anticoagulation entails. No clear benefits of edoxaban have been reported to date compared to the other available factor Xa inhibitors.
Export Options
About this article
Cite this article as:
Switzer Popp Maryna, Wani Priyanka, Gosavi Sucheta and Mukherjee Debabrata, Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (2) . https://dx.doi.org/10.2174/187152571302151217130638
DOI https://dx.doi.org/10.2174/187152571302151217130638 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Coronary Collateral Circulation in Man
Current Cardiology Reviews Old Versus New Anticoagulants: Focus on Pharmacology
Recent Patents on Cardiovascular Drug Discovery Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry Comparison of Postpartum Hemoglobin and Hematocrit Levels In Conventional and Physiological Delivery in Iran: A Quasi-Experimental Study
Current Women`s Health Reviews Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Low Molecular Weight Heparin: Current Evidence for Its Application in Orthopaedic Surgery
Current Vascular Pharmacology From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Methods of Assessment of Insulin Sensitivity and β-Cell Function
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Placental Cytokines in the Pathogenesis of Preeclampsia and Hellp Syndrome
Current Women`s Health Reviews Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry Alkannins and Shikonins: A New Class of Wound Healing Agents
Current Medicinal Chemistry Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Magnetic Resonance Contrast Media Sensing In Vivo Molecular Imaging Agents: An Overview
Current Radiopharmaceuticals The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry